## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.5% below STRENGTH zone (3.0-6.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($741.48)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors**
- Source: Simply Wall Street | 20260106T162820 | Somewhat-Bullish | Relevance: 100%
- Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for the treatment of severe or refractory bronchial asthma in children aged 6 to 11. This approval expands Dupixent's market and reinforces its role in allergic and inflammatory diseases, which is a positive for Regeneron, but the main investment drivers remain EYLEA competition and efficient R&D spending. Investors should monitor Regeneron's upcoming Q4 and full-year 2025 results on January 30, 2026, for more details on Dupixent's performance and pediatric asthma uptake.

**2. How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors**
- Source: Simply Wall Street | 20260106T160918 | Neutral | Relevance: 100%
- Regeneron Pharmaceuticals received marketing authorization in Japan for Dupixent to treat severe pediatric asthma, expanding the drug's patient base. This approval reinforces Dupixent's importance, but investors should also monitor the upcoming Q4 2025 results for its overall performance and any management outlook on pediatric asthma uptake. While some analysts have bullish revenue expectations for Regeneron, pricing and reimbursement risks for high-cost biologics remain a key consideration.

**3. Looking at the Latest Short Interest Trends for Regeneron Pharmaceuticals Inc**
- Source: Bitget | 20260106T020837 | Somewhat-Bullish | Relevance: 100%
- Regeneron Pharmaceuticals Inc (NYSE: REGN) has seen a 12.97% decrease in short interest, now standing at 2.75% of its float, indicating a potential shift towards increasing optimism among investors. This short interest percentage is notably lower than the average of 7.46% among its industry peers. The stock's current price is $774.88, with a recent increase of 1.53%.

**4. Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20260105T083300 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 18.9% in Q3, selling 6,253 shares and retaining 26,800 shares valued at $16.08 million. The company has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $779.45. Insider selling has also occurred, with Director Christine A. Poon selling 6,500 shares for $4.25 million, though insiders still own approximately 7.02% of the company.

**5. The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson**
- Source: The Globe and Mail | 20260106T110918 | Bullish | Relevance: 100%
- This Zacks Analyst Blog highlights five medical sector stocks that are leveraging AI to drive growth and innovation: Eli Lilly and Co., Medtronic plc, Intuitive Surgical Inc., Regeneron Pharmaceuticals Inc., and Johnson & Johnson. The article details how each company uses AI in drug discovery, medical devices, surgical systems, and diagnostics to enhance patient care and operational efficiency, making them strong portfolio contenders for 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($108.80M) |
| Sells | 16 ($13.47M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $13M sold (16 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Insider buying signal ($108.8M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.3B |
| Beta | 0.39 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 20.0 |
| Current P/E | 18.0 |
| YoY Growth | -10.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.57), momentum weakening. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.54% (CS: 29) | Neutral |
| RSI_14 | 60.5 | Neutral |
| MACD Histogram | -2.57 | Bearish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.080x | Above |
| vs SMA200 | 1.283x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $776.54
- **Stop Loss:** $741.48 (4.5% risk)
- **Target:** $811.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $28,731.98
- **Portfolio %:** 28.73%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*